<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296932</url>
  </required_header>
  <id_info>
    <org_study_id>1270.1</org_study_id>
    <secondary_id>2010-021488-34</secondary_id>
    <nct_id>NCT01296932</nct_id>
  </id_info>
  <brief_title>BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)</brief_title>
  <official_title>A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two
      prior treatment regimens may be enrolled in this trial. The trial will examine whether
      monotherapy with BI 836826 is safe and tolerable at escalating dose levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2011</start_date>
  <completion_date type="Actual">May 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the maximum tolerated dose of BI 836826</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lymphocytes in the peripheral blood</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour size</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood counts</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Patients with relapsed CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836826</intervention_name>
    <description>Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.</description>
    <arm_group_label>Patients with relapsed CLL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of relapsed or refractory chronic lymphocytic leukaemia.

          2. At least two prior treatment regimens for chronic lymphocytic leukaemia.

          3. At least one criterion for active disease as defined by the International Workshop on
             CLL.

          4. Absolute lymphocyte count lower than 200 x 10^9/l .

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2.

          6. Age 18 years or older.

          7. Written informed consent which is consistent with International Conference on
             Harmonisation - Good Clinical Practice (ICH-GCP) guidelines and local legislation.

        Exclusion criteria:

          1. Treatment with anti CD 20 therapy within 4 weeks, or alemtuzumab within 8 weeks, or
             any cytotoxic antileukemia therapy within 2 weeks, Ibrutinib or Idelalisib within 1
             week prior to the first administration of the trial drug.

          2. Prior allogeneic stem cell transplantation.

          3. Active autoimmune haemolytic anemia.

          4. Active autoimmune thrombocytopenia.

          5. Known transformation to an aggressive B-cell malignancy.

          6. Concurrent treatment with relevant doses of systemic glucocorticosteroids.

          7. Prior history of malignancy other than chronic lymphocytic leukaemia (exceptions to
             this rule are defined in the clinical trial protocol).

          8. Aspartate aminotransferase or alanine aminotransferase &gt; 2.5 x upper limit of normal.

          9. Total bilirubin &gt; 1.5 x upper limit of normal.

         10. Absolute Neutrophil Count &lt; 1.000/µl.

         11. Platelets &lt; 25.000/µL.

         12. Estimated Glomerular Filtration Rate &lt;45 mL/min.

         13. Proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher.

         14. Significant concurrent disease.

         15. Any infectious disease requiring treatment at the time of enrolment or within the
             previous 2 weeks.

         16. Hepatitis B or C.

         17. Human Immunodeficiency Virus (HIV) infection.

         18. Cytomegalovirus (CMV) viremia.

         19. Women of childbearing potential not using a highly effective method of birth control
             during the trial until one year after the last dose.

         20. Pregnancy or breast feeding.

         21. Known or suspected active alcohol or drug abuse.

         22. Treatment with another investigational drug within the past four weeks before start of
             therapy or concomitantly with this trial.

         23. Prior treatment with BI 836826.

         24. Patients unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brussels - UNIV St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edegem - UNIV UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gent - UNIV UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INS Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTR Investigation Clinique, onco, Montpellier</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INS Universitaire du Cancer</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

